Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tests whether the experimental drug AL2846 can slow cancer growth in people with advanced thyroid cancer that no longer responds to radioiodine or previous targeted therapy. About 144 participants will receive either AL2846 or a placebo. The main goal is to see how lon…

This study tests a new drug, rovadicitinib, for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The goal is to see if rovadicitinib improves symptoms better than sta…

This study tests an injection called TQH2722 for people with severe chronic sinusitis, with or without nasal polyps. The goal is to see if it is safe and works well over a long period. About 120 adults aged 18 to 75 who completed a prior related study will take part.

This early-phase study tests a new oral drug, TQB3122, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow disease. About 86 adults aged 18-75 wi…

This study tests a new drug, TQB6411, in people with advanced esophageal cancer that has come back or spread and no longer responds to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or slow the disease. About 105 participants aged 18-75 will …

This early-phase study tests a new oral drug, TQB3205, in 156 adults with advanced malignant tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking for any signs that the drug shrinks tumors. Pa…

This study tests a new drug called LM-108, given with other cancer drugs (penpulimab and chemotherapy), in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can help control the disease or extend life. About 72 adults with advanced pancreat…

This study tests a new drug called TQB2825 combined with standard immune-chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) who have not been treated before or whose cancer has come back. The goal is to see if the combination shrinks tumors and controls the diseas…

This study tests whether combining two experimental drugs (TQ05105 and TQB3617) can safely shrink the spleen and improve symptoms in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. About 92 adults will take the pills daily, and researchers will…

This early-stage study tests a new drug, TQB3002, in 150 adults with advanced cancers that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look for …

This study tests a combination of two drugs (benmelstobart and anlotinib) in 33 people aged 14 and older with advanced or inoperable alveolar soft part sarcoma, a rare cancer. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants will recei…

This study tests an experimental drug called TQH2929 for people with a rare and severe form of psoriasis that causes sudden, painful pustules all over the body. The trial will involve 36 adults who are currently having a flare-up. Half will get the drug, half a placebo, to see if…

This study tests a new drug called TQB6411 in people with advanced lung cancer. The goal is to find the best dose and see if it shrinks tumors. About 465 adults aged 18 to 75 with good overall health will take part. The study is currently recruiting.

This study tests whether a new drug called TQ-B3234 can shrink non-surgical nerve tumors (plexiform neurofibromas) in adults with neurofibromatosis type 1 (NF1). About 177 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces tumor si…

This early-stage study tests an experimental oral drug called TQB3019 in 80 adults with advanced malignant tumors that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors…

This early-stage study tests a new medicine called TQF3250 in healthy adults to see if it is safe and how the body processes it. The drug is designed to help control blood sugar by activating certain pathways in the body while avoiding others, which may lead to better results and…

This early-phase study looks at how the drug TQ05105 behaves in people with mild or moderate liver impairment compared to healthy volunteers. About 24 adults will receive a single dose to measure drug levels and safety. The goal is to understand dosing needs, not to treat the dis…